196MO Anlotinib plus etoposide/carboplatin (EC) versus placebo plus EC in first-line therapy for extensive-stage small cell lung cancer (ES-SCLC): A randomized, double-blind, parallel controlled, phase III trial (ETER 701)

Y. Cheng, R. Yang, J. Chen,W. Zhang, C. Xie, Q. Hu,N. Zhou, C. Huang, S. Wei, H. Sun,X. Li,Y. Yu, J. Lai, H. Yang, H. Fang,H. Chen, P. Zhang, K. Gu, Q-M. Wang, J. Shi

ESMO Open（2024）

引用 0|浏览10